Table 4. Reported incidence of AEs with other regimens.

	Lembersky et al (2006)				Twelves et al (2005)		André et al (2004)
	UFT/LV (n=774)		i.v. 5-FU/LVa (n=759)		Capecitabine (n=995)		FOLFOX4 (n=1108)
Events	Any grades (%)	⩾Grade 3 (%)	Any grades (%)	⩾Grade 3 (%)	Any grades (%)	⩾Grade 3 (%)	Any grades (%)	⩾Grade 3 (%)
Clinical findings
Stomatitis	26	1.3	24	0.5	22	2	42	3
Nausea	54	7	65	7	36	3	74	5
Vomiting	28	4	31	7			47	6
Diarrhoea	75	29	79	29	46	11	56	11
Skin disorders	22b	1.3b	20b	1.1b	—	—	32b	2b
HFS	—	0.7	—	0.2	60	17	—	—
Paraesthesia	—	—	—	—	—	—	92	12
Laboratory findings
Leukocytes	17	0	22	0.7	<10	—	—	—
Granulocytes	20	1.3	27	1.3	32	2	79	41
Haemoglobin	—	—	—	—	<10	—	76	0.8
Platelets	—	—	—	—	<10	—	77	1.7
Total bilirubin	7	0.3	4	—	50	20	—	—

Abbreviations: AEs=adverse events; FOLFOX=5-FU/LV plus oxaliplatin; HFS=hand–foot syndrome; i.v.=intravenous; LV=leucovorin.

^aTreatment schedule reported from the Roswell Park Memorial Institute.

^bIncluding HFS.